Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Meiji Seika Pharma Co. Ltd.

Division of Meiji Holdings Co. Ltd.
www.meiji-seika-pharma.co.jp/english/

Latest From Meiji Seika Pharma Co. Ltd.

No Panic At Newron Over Delayed Schizophrenia Drug Trial

Although the US FDA raised concerns about a rat toxicity trial, causing shares to slide, Italy's Newron believes the trial delay for schizophrenia therapy evenamide is just a blip.

Drug Safety Neurology

QIDP Roundup: Familiar Names Dominate 2019 Designations

US FDA's Qualified Infectious Disease Product program is growing slowly, but still growing.

Review Pathway Infectious Diseases

Asia Deal Watch: Boost For Esperion's Cholesterol Candidate As Daiichi Brought On Board

Daiichi Sankyo pays $150m upfront to commercialize Esperion's cholesterol drug and combination in Europe, while Gilead enters major deal worth up to $785m with Korea's Yuhan to bolster its NASH portfolio. Samsung taps 3SBio to build its biosimilars business in China. 
Deals Asia Pacific

Humira Biosimilars Face Complex Asia Outlook As Launches Edge Closer

The Asia Pacific region presents large potential opportunities for the development of biosimilar versions of big-selling original biologics as these come out of protection in the major markets. However the regulatory, reimbursement and commercial situation varies greatly country-by-country, presenting a complex mix of factors affecting the overall market outlook for these up and coming biosimilar products.

Asia Pacific Biosimilars
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Generic Drugs
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Infectious & Viral Diseases
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Asia
      • Pacific Rim
        • Japan
  • Parent & Subsidiaries
  • Meiji Holdings Co. Ltd.
  • Senior Management
  • Daikichiro Kobayashi, PhD, Pres.
  • Contact Info
  • Meiji Seika Pharma Co. Ltd.
    Phone: (81) 3-3272-6511
    4-16 Kyobashi 2-chome, Chuo-ku
    Tokyo , 104-8002
    Japan
Advertisement
Advertisement
UsernamePublicRestriction

Register